Posted by Michael Wonder on 05 Jun 2017
Prima’s trial backs safety of metastatic breast cancer drug
5 June 2017 - The Lucy Turnbull-chaired biotech Prima Biomed has revealed new data that backs the safety of its metastatic breast cancer drug.
The Australian-listed company released the results of its most recent trial at the annual meeting of the American Society of Clinical Oncology in Chicago.
Chief executive Marc Voigt said Prima Biomed was excited by the data because the trial was based on an increase in the dosage of its immunotherapy drug but the safety profile was still mild.
